IRB# 19384 PHASE 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome

Squamous cell carcinoma (SCC)

No studies available

Basal Cell Carcinoma (BCC)

No studies available

Other types

No studies available

IRB#19384 PHASE 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome

IRB 19829 A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Non-Melanoma

Please refer to Phase I studies for more clinical trial opportunities and to the Melanoma flowsheet for Melanoma related studies.

STUDY00020518: CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY

http://www.ohsu.edu/research/rda/so/knight.php

18 OCT 2019